4DMedical Ltd

4DMedical (ASX: 4DX) has secured three significant agreements to expand the reach of its lung health imaging technology. In Australia, 4DMedical has locked in a multi-year deal with Spectrum Medical Imaging to support the National Lung Cancer Screening Program. The company will also launch a Brazilian lung screening program with a leading pharmaceutical partner, while […]

4DMedical (ASX: 4DX) has received reimbursement approval from the US Centers for Medicare & Medicaid Services (CMS) for its CT:VQ lung imaging platform. The decision follows Food and Drug Administration (FDA) clearance granted last week, aligning regulatory authorisation with a defined payment structure. Together, the approvals clear the path for commercial rollout of the software […]

4DMedical (ASX: 4DX) has received United States Food and Drug Administration (FDA) clearance for its CT:VQ software, marking a major milestone in respiratory diagnostics. The technology is the world’s first non-contrast CT-based ventilation-perfusion tool to replace nuclear medicine scans currently used to assess airflow and blood flow in the lungs. The clearance opens a potential […]

4DMedical (ASX: 4DX) will lend its ground-breaking analytical software to two industry partners working to bring new lung disease therapies to market. US-based SMS Biotech will use the company’s suite of software tools for a trial of its novel human stem cell therapy for the treatment of chronic obstructive pulmonary disease (COPD) and an undisclosed […]